JP2023518430A - 感染症の治療におけるブシラミンの使用 - Google Patents

感染症の治療におけるブシラミンの使用 Download PDF

Info

Publication number
JP2023518430A
JP2023518430A JP2022556099A JP2022556099A JP2023518430A JP 2023518430 A JP2023518430 A JP 2023518430A JP 2022556099 A JP2022556099 A JP 2022556099A JP 2022556099 A JP2022556099 A JP 2022556099A JP 2023518430 A JP2023518430 A JP 2023518430A
Authority
JP
Japan
Prior art keywords
therapeutically effective
effective amount
use according
bucillamine
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518430A5 (https=
Inventor
アンドレア キアネッリ、ファビオ
フランク、マイケル
Original Assignee
リバイヴ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リバイヴ セラピューティクス リミテッド filed Critical リバイヴ セラピューティクス リミテッド
Publication of JP2023518430A publication Critical patent/JP2023518430A/ja
Publication of JP2023518430A5 publication Critical patent/JP2023518430A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022556099A 2020-03-19 2021-03-16 感染症の治療におけるブシラミンの使用 Pending JP2023518430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991996P 2020-03-19 2020-03-19
US62/991,996 2020-03-19
PCT/CA2021/050350 WO2021184115A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases

Publications (2)

Publication Number Publication Date
JP2023518430A true JP2023518430A (ja) 2023-05-01
JP2023518430A5 JP2023518430A5 (https=) 2024-02-02

Family

ID=77767915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556099A Pending JP2023518430A (ja) 2020-03-19 2021-03-16 感染症の治療におけるブシラミンの使用

Country Status (5)

Country Link
US (1) US20230172884A1 (https=)
EP (1) EP4121035A4 (https=)
JP (1) JP2023518430A (https=)
KR (1) KR20230015320A (https=)
WO (1) WO2021184115A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183146A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130039928A1 (en) * 2010-01-28 2013-02-14 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9238018B2 (en) * 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
CA3017797A1 (en) * 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130039928A1 (en) * 2010-01-28 2013-02-14 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRITIKA KHANNA ET AL.: ""Binding of SARS-CoV-2 spike protein to ACE2 is disabled bythiol-based drugs; evidence from in vitr", BIORXIV, JPN6025008791, 8 December 2020 (2020-12-08), ISSN: 0005677603 *

Also Published As

Publication number Publication date
US20230172884A1 (en) 2023-06-08
EP4121035A1 (en) 2023-01-25
WO2021184115A1 (en) 2021-09-23
EP4121035A4 (en) 2024-04-24
KR20230015320A (ko) 2023-01-31
CA3172170A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EP1484059B1 (en) Antiviral compositions comprising phenylacetic acid derivatives
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
JPWO2023054732A5 (https=)
BG60400B2 (bg) Синергитични фармацевтични препарати, тяхното получаване и употребата им
HU228026B1 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
JP2023518430A (ja) 感染症の治療におけるブシラミンの使用
JP2004091473A (ja) 色素沈着改善治療薬
EP1970061A1 (en) Medicinal agent for treating viral infections
CA3172170C (en) Use of bucillamine in the treatment of infectious diseases
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
EP4159214B1 (en) Composition for treating, improving, and/or preventing progression of bovine papillomatosis caused by bovine papillomavirus
WO2008038423A1 (fr) Composition antiphlogistique et analgésique pour une utilisation orale
CN110891574B (zh) 用于预防和/或治疗肝细胞癌的美格列明
JP2002540150A (ja) ウイルス治療
WO2006043336A1 (ja) 胃粘膜疾患の治療又は予防のための組成物
HUT55630A (en) Process for producing pharmaceutical compositions for lowering trigliceride and cholesterol level and highering level of lipoprotheines of high density
CN114401724B (zh) 一种降糖药物组合物
US12029771B2 (en) Neem for treatment of RLS
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
CN111228247B (zh) 一种用于治疗包虫病的含苯亚甲基丙酮药物及其制备方法
US20060287364A1 (en) Methods of prevention of infection with HIV/AIDS, venereal disease and influenza
TWI393562B (zh) 左旋丁基苯酞在製備預防和治療腦梗塞的藥物中的應用
CN106265112A (zh) 促进伤口愈合的药物、化妆用组合物和食品添加剂
US11090290B2 (en) Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902